What is MASH?
MASH (Metabolic dysfunction-associated steatohepatitis) is the progressive, inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by hepatic fat accumulation, hepatocyte ballooning, and liver inflammation that can progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. 1
Disease Definition and Pathology
MASH represents the hepatic manifestation of metabolic syndrome and is fundamentally a multi-organ disease 2. The key histologic features that distinguish MASH from simple steatosis include:
- Steatosis (fat accumulation in hepatocytes)
- Hepatocyte ballooning (cellular injury)
- Lobular inflammation (immune cell infiltration)
- Progressive fibrosis (scarring that leads to cirrhosis) 1, 3
Epidemiology and Prevalence
MASH affects a substantial portion of the global population:
- MASLD (the broader disease category) affects 30-40% of adults worldwide 3
- Among those with MASLD, up to 20% develop MASH 4
- Prevalence is dramatically higher in metabolic disease: 60-70% of individuals with type 2 diabetes and 70-80% of those with obesity have MASLD 3
- The male-to-female ratio is approximately 2:1 3
Pathophysiology
MASH pathogenesis involves multiple parallel mechanisms 4:
- Insulin resistance (permits persistent gluconeogenesis while amplifying lipogenesis) 5
- Hepatic lipotoxicity (toxic lipid metabolites damage hepatocytes)
- Adipose tissue dysfunction (failed peripheral lipid buffering forces lipid burden onto the liver) 6
- Immune-mediated inflammation (innate and adaptive immune activation)
- Gut-liver axis perturbations (intestinal dysbiosis contributing to inflammation) 2, 4
- Genetic risk variants (polygenic risk scores enable risk stratification) 2
Clinical Significance and Mortality
Cardiovascular disease is the leading cause of death in MASH patients, followed by extrahepatic cancers (gastrointestinal, breast, gynecologic) and liver-related complications 3. The liver-specific complications include:
- Cirrhosis
- Hepatic decompensation (ascites, encephalopathy, variceal bleeding)
- Hepatocellular carcinoma
- Need for liver transplantation 1, 7
MASH patients have a significantly higher mortality rate compared to the general population or those with simple steatosis 8.
Nomenclature Update
MASH was previously termed NASH (nonalcoholic steatohepatitis), and MASLD was formerly known as NAFLD (nonalcoholic fatty liver disease) 1. The updated terminology better reflects the metabolic dysfunction driving the disease rather than defining it by the absence of alcohol.
Diagnostic Criteria
MASLD/MASH is diagnosed when hepatic steatosis is present (typically by ultrasound) along with at least 1 of 5 metabolic syndrome features:
- Abdominal overweight or obesity
- Prediabetes or type 2 diabetes
- Hypertension
- Elevated plasma triglycerides
- Low HDL cholesterol 3
Alcohol consumption must be <140 g/week for women (<2 drinks/day) and <210 g/week for men (<3 drinks/day), with no other causes of steatosis present 3.